At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VOR Vor Biopharma Inc.
Post-Mkt 11-05 17:08:54 EST
18.66
-1.46
-7.26%
盘后18.21
-0.45-2.41%
17:06 EST
High20.08Low18.33Vol632.75K
Open20.08D1 Closing20.12Amplitude8.70%
Mkt Cap1.15BTradable Cap737.09MTotal Shares61.43M
T/O11.93MT/O Rate1.60%Tradable Shares39.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Robert W. Baird Remains a Buy on Vor Biopharma (VOR)
TIPRANKS  ·  11-03
Robert W. Baird Remains a Buy on Vor Biopharma (VOR)
Axsome Therapeutics Q3 Revenue Rises on Auvelity and Sunosi
Reuters  ·  11-02
Axsome Therapeutics Q3 Revenue Rises on Auvelity and Sunosi
Vor Biopharma Stock Gets A Lift From Kidney Disease Trial Results
Simply Wall St.  ·  10-31
Vor Biopharma Stock Gets A Lift From Kidney Disease Trial Results
Vor Biopharma - Enters Sales Agreement with William Blair and RBC Capital Markets on Oct 30, 2026 - SEC Filing
THOMSON REUTERS  ·  10-30
Vor Biopharma - Enters Sales Agreement with William Blair and RBC Capital Markets on Oct 30, 2026 - SEC Filing
Vor Biopharma - May Offer Common Stock with Aggregate Offering Price up to $150 Mln - SEC Filing
THOMSON REUTERS  ·  10-30
Vor Biopharma - May Offer Common Stock with Aggregate Offering Price up to $150 Mln - SEC Filing
Vor Biopharma Q3 Net Loss Widens on Higher Expenses
Reuters  ·  10-30
Vor Biopharma Q3 Net Loss Widens on Higher Expenses
Vor Bio Q3 2026 Net Loss Narrows 89% to $86.7 Million
Reuters  ·  10-30
Vor Bio Q3 2026 Net Loss Narrows 89% to $86.7 Million
Vor Biopharma - Cash and Investment Balance $481.60 Mln as of Sept 30, 2026; Runway into Early 2029
THOMSON REUTERS  ·  10-30
Vor Biopharma - Cash and Investment Balance $481.60 Mln as of Sept 30, 2026; Runway into Early 2029
Vor Biopharma - Enrollment Ongoing for Phase 3 Upstream Sjd Trial in Primary SjÖGren’s Disease
THOMSON REUTERS  ·  10-30
Vor Biopharma - Enrollment Ongoing for Phase 3 Upstream Sjd Trial in Primary SjÖGren’s Disease
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
THOMSON REUTERS  ·  10-30
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Vor Biopharma Q3 Net Income USD -86.7 Million VS. Ibes Estimate USD -47.2 Million
THOMSON REUTERS  ·  10-30
Vor Biopharma Q3 Net Income USD -86.7 Million VS. Ibes Estimate USD -47.2 Million
Vor Bio Says Its Experimental Drug Slowed Loss of Kidney Function in Late-Stage Study
Reuters  ·  10-23
Vor Bio Says Its Experimental Drug Slowed Loss of Kidney Function in Late-Stage Study
Vor Bio’s telitacicept meets primary endpoint in Phase 3 kidney trial
TIPRANKS  ·  10-23
Vor Bio’s telitacicept meets primary endpoint in Phase 3 kidney trial
Vor Biopharma - Telitacicept Reduces Risk of ≥30% Egfr Decline by 89% and ≥40% Decline by 81%
THOMSON REUTERS  ·  10-23
Vor Biopharma - Telitacicept Reduces Risk of ≥30% Egfr Decline by 89% and ≥40% Decline by 81%
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 Teligan Trial in Iga Nephropathy
THOMSON REUTERS  ·  10-23
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 Teligan Trial in Iga Nephropathy
Vor Biopharma - no Kidney Failure Events in Telitacicept Group; Five Events in Placebo Including Two Requiring Dialysis
THOMSON REUTERS  ·  10-23
Vor Biopharma - no Kidney Failure Events in Telitacicept Group; Five Events in Placebo Including Two Requiring Dialysis
Vor Biopharma - Telitacicept Sustains Proteinuria Reduction Through 104 Weeks with Favorable Safety Profile
THOMSON REUTERS  ·  10-23
Vor Biopharma - Telitacicept Sustains Proteinuria Reduction Through 104 Weeks with Favorable Safety Profile
Vor Biopharma Inc. : William Blair Initiates Coverage with Outperform Rating
THOMSON REUTERS  ·  10-21
Vor Biopharma Inc. : William Blair Initiates Coverage with Outperform Rating
William Blair Initiates Vor Biopharma at Outperform
MT Newswires Live  ·  10-21
William Blair Initiates Vor Biopharma at Outperform
Vor Bio initiated with an Outperform at William Blair
TIPRANKS  ·  10-21
Vor Bio initiated with an Outperform at William Blair

Introduction

Company Name.
Vor Biopharma Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Issue price:
--